Won et al. BMC Cancer 2010, 10:564 http://www.biomedcentral.com/1471-2407/10/564 5. Andino L, Cagle PT, Murer B, Lu L, Popper HH, Galateau-Salle F, Sienko AE, Barrios R, Zander DS: Pleuropulmonary desmoid tumors: immunohistochemical comparison with solitary fibrous tumors and assessment of beta-catenin and cyclin D1 expression. Arch Pathol Lab Med 2006, 130(10):1503-1509. 6. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M, Kaibara N: The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma. Br J Cancer 1999, 81(3):484-489. 7. Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, Roh MS, Kim DC, Park KJ, Choi HJ, Kim HJ: Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am J Clin Oncol 2009, 32(1):38-43. 8. Song KY, Jung CK, Park WS, Park CH: Expression of the antiapoptosis gene Survivin predicts poor prognosis of stage III gastric adenocarcinoma. Jpn J Clin Oncol 2009, 39(5):290-296. 9. Liebig C, Ayala G, Wilks JA, Berger DH, Albo D: Perineural invasion in cancer: a review of the literature. Cancer 2009, 115(15):3379-3391. 10. Kim WB, Han HJ, Lee HJ, Park SS, Song TJ, Kim HK, et al: Expression and clinical significance of cell cycle regulatory proteins in gallbladder and extrahepatic bile duct cancer. Ann Surg Oncol 2009, 16(1):23-34. 11. Jarnagin WR, Klimstra DS, Hezel M, Gonen M, Fong Y, Roggin K, et al: Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol 2006, 24(7):1152-1160. 12. Shen YC, Hu FC, Jeng YM, Chang YT, Lin ZZ, Chang MC, et al: Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: correlation with clinicopathologic features and patient survival. Cancer Epidemiol Biomarkers Prev 2009, 18(2):417-423. 13. Hui AM, Cui X, Makuuchi M, Li X, Shi YZ, Takayama T: Decreased p27(Kip1) expression and cyclin D1 overexpression, alone and in combination, influence recurrence and survival of patients with resectable extrahepatic bile duct carcinoma. Hepatology 1999, 30(5):1167-1173. 14. Javle MM, Tan D, Yu J, LeVea CM, Li F, Kuvshinoff BW, Gibbs JF: Nuclear survivin expression predicts poor outcome in cholangiocarcinoma. Hepatogastroenterology 2004, 51(60):1653-1657. 15. Uchida K, Danenberg PV, Danenberg KD, Grem JL: Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine. BMC Cancer 2008, 8:386. 16. Ahn MJ, Choi JH, Oh HS, Lee YY, Kim IS, Choi IY, et al: Thymidylate Synthase, Thymidine Phosphorylase, VEGF and p53 Protein Expression in Primary Colorectal Cancer for Predicting Response to 5-fluorouracil- based Chemotherapy. Cancer Res Treat 2005, 37(4):216-222. 17. Kim TW, Chang HM, Kang HJ, Lee JR, Ryu MH, Ahn JH, et al: Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 2003, 14(7):1115-1120. 18. Hong YS, Lee J, Lee SC, Hwang IG, Choi SH, Heo JS, et al: Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Cancer Chemother Pharmacol 2007, 60(3):321-328. 19. Nehls O, Oettle H, Hartmann JT, Hofheinz RD, Hass HG, Horger MS, et al: Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 2008, 98(2):309-315. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/10/564/prepub doi:10.1186/1471-2407-10-564 Cite this article as: Won et al.: Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer. BMC Cancer 2010 10:564. Page 8 of 8 Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color ﬁgure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit